Literature DB >> 20188247

Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants.

Dennis M Klinman1, Sven Klaschik, Koji Tomaru, Hidekazu Shirota, Debra Tross, Hidekazu Ikeuchi.   

Abstract

Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs mimic the immunostimulatory activity of bacterial DNA. CpG ODN directly stimulate B cells and plasmacytoid dendritic cells (pDC), promote the production of Th1 and pro-inflammatory cytokines, and trigger the maturation/activation of professional antigen presenting cells. CpG ODN are finding use as vaccine adjuvants, where they increase the speed, magnitude and duration of vaccine-specific immune responses. For example, CpG ODN significantly prolong the protection induced by AVA (Anthrax Vaccine Adsorbed). Unexpectedly, a majority of animals immunized with CpG-adjuvanted AVA maintain resistance to anthrax infection even after their Ab titers decline to sub-protective levels. This survival is mediated by the de novo production of protective Abs by high affinity long-lived memory B cells. The immunostimulatory activity of CpG ODN was probed at the molecular level by microarray. Results show that a small group of 'inducers' rapidly up-regulated a large network genes following CpG treatment of mice. This stimulatory activity is quenched by 'suppressors' that down-regulate the expression of targeted genes, including most of the 'inducers'. These findings shed light on the mechanism underlying CpG-mediated immune activation and therapeutic activity. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20188247      PMCID: PMC2830905          DOI: 10.1016/j.vaccine.2009.10.094

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  Bioterrorism: a clear and present danger.

Authors:  H C Lane; J L Montagne; A S Fauci
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

3.  Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo.

Authors:  Sven Klaschik; Debra Tross; Dennis M Klinman
Journal:  J Leukoc Biol       Date:  2009-01-29       Impact factor: 4.962

4.  Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12.

Authors:  A Krug; A Towarowski; S Britsch; S Rothenfusser; V Hornung; R Bals; T Giese; H Engelmann; S Endres; A M Krieg; G Hartmann
Journal:  Eur J Immunol       Date:  2001-10       Impact factor: 5.532

5.  Anthrax vaccine: short-term safety experience in humans.

Authors:  P R Pittman; P H Gibbs; T L Cannon; A M Friedlander
Journal:  Vaccine       Date:  2001-12-12       Impact factor: 3.641

6.  Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide.

Authors:  Mayda Gürsel; Daniela Verthelyi; Ihsan Gürsel; Ken J Ishii; Dennis M Klinman
Journal:  J Leukoc Biol       Date:  2002-05       Impact factor: 4.962

7.  Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells.

Authors:  F Takeshita; C A Leifer; I Gursel; K J Ishii; S Takeshita; M Gursel; D M Klinman
Journal:  J Immunol       Date:  2001-10-01       Impact factor: 5.422

8.  Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.

Authors:  Veit Hornung; Simon Rothenfusser; Stefanie Britsch; Anne Krug; Bernd Jahrsdörfer; Thomas Giese; Stefan Endres; Gunther Hartmann
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

9.  Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens.

Authors:  N Kadowaki; S Ho; S Antonenko; R W Malefyt; R A Kastelein; F Bazan; Y J Liu
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

10.  Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation.

Authors:  Ken J Ishii; Fumihiko Takeshita; Ihsan Gursel; Mayda Gursel; Jacqueline Conover; Andre Nussenzweig; Dennis M Klinman
Journal:  J Exp Med       Date:  2002-07-15       Impact factor: 14.307

View more
  16 in total

Review 1.  DNA vaccines for targeting bacterial infections.

Authors:  Mariana Ingolotti; Omkar Kawalekar; Devon J Shedlock; Karuppiah Muthumani; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2010-07       Impact factor: 5.217

2.  A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis.

Authors:  Catpagavalli Asokanathan; Michael Corbel; Dorothy Xing
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

3.  Plasmodium falciparum: differential merozoite dose requirements for maximal production of various inflammatory cytokines.

Authors:  Xianzhu Wu; Nagaraj M Gowda; D Channe Gowda
Journal:  Exp Parasitol       Date:  2010-08-03       Impact factor: 2.011

4.  TLR-Induced Murine Dendritic Cell (DC) Activation Requires DC-Intrinsic Complement.

Authors:  Joong-Hyuk Sheen; Michael G Strainic; Jinbo Liu; Weijia Zhang; Zhengzi Yi; M Edward Medof; Peter S Heeger
Journal:  J Immunol       Date:  2017-05-24       Impact factor: 5.422

5.  A suppressive oligodeoxynucleotide expressing TTAGGG motifs modulates cellular energetics through the mTOR signaling pathway.

Authors:  Volkan Yazar; Gizem Kilic; Ozlem Bulut; Tugce Canavar Yildirim; Fuat C Yagci; Gamze Aykut; Dennis M Klinman; Mayda Gursel; Ihsan Gursel
Journal:  Int Immunol       Date:  2020-01-09       Impact factor: 4.823

6.  Investigation of phosphorylated adjuvants co-encapsulated with a model cancer peptide antigen for the treatment of colorectal cancer and liver metastasis.

Authors:  Tyler J Goodwin; Leaf Huang
Journal:  Vaccine       Date:  2017-04-03       Impact factor: 3.641

7.  Vaccination with Toxoplasma lysate antigen and CpG oligodeoxynucleotides: comparison of immune responses in intranasal versus intramuscular administrations.

Authors:  Mohamed A EL-Malky; Saeed A Al-Harthi; Raafat T Mohamed; Mohamed A EL Bali; Niveen S Saudy
Journal:  Parasitol Res       Date:  2014-04-13       Impact factor: 2.289

8.  Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.

Authors:  Petr O Ilyinskii; Christopher J Roy; Conlin P O'Neil; Erica A Browning; Lynnelle A Pittet; David H Altreuter; Frank Alexis; Elena Tonti; Jinjun Shi; Pamela A Basto; Matteo Iannacone; Aleksandar F Radovic-Moreno; Robert S Langer; Omid C Farokhzad; Ulrich H von Andrian; Lloyd P M Johnston; Takashi Kei Kishimoto
Journal:  Vaccine       Date:  2014-03-01       Impact factor: 3.641

Review 9.  The impact of "omic" and imaging technologies on assessing the host immune response to biodefence agents.

Authors:  Julia A Tree; Helen Flick-Smith; Michael J Elmore; Caroline A Rowland
Journal:  J Immunol Res       Date:  2014-09-16       Impact factor: 4.818

10.  Characterization of Innate Responses Induced by PLGA Encapsulated- and Soluble TLR Ligands In Vitro and In Vivo in Chickens.

Authors:  Tamiru N Alkie; Khaled Taha-Abdelaziz; Neda Barjesteh; Jegarubee Bavananthasivam; Douglas C Hodgins; Shayan Sharif
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.